APR 21, 2021 11:59 AM PDT

Dietary Supplement Successfully Treats Mice with Schizophrenia

WRITTEN BY: Annie Lennon

Researchers from the University of Tokyo have found that betaine, a dietary supplement found in sugar beets, reduces behavioural symptoms of schizophrenia in mice with a genetic predisposition to the condition.  

The kinesin superfamily of genes in mammals mostly encodes motor protons that move materials throughout the cell. Genetic studies of people diagnosed with schizophrenia show that people with the condition tend to have variations in the kinesin family 3b (kif3b) gene as well as another involved in the body’s internal synthesis of betaine. 

As such, mouse models of schizophrenia usually have only one functional copy of the kif3b gene. These mice tend to avoid social interactions and have similar reactions to humans in tests measuring how startled they become after sudden, loud sounds proceeded by quieter ones. 

For the study, researchers raised mice with this schizophrenia model on betaine supplements at three times the normal dietary requirement. In doing so, the mice were observed to have normal behaviour, meaning that the supplement may be able to treat symptoms of schizophrenia.

 To understand how this may work, the researchers then grew nerve cells with the kif3b mutation in the lab and added fluorescent labels to them to map their development. These kif3b mutant neurons tended to have more branches than regular neurons, something also observed in brain samples donated by patients with schizophrenia regardless of their treatments. 

In observing the cells more closely, the researchers found that the presence of skeleton components in neuron development known as tubulin and actin differed from that observed in normal cells. A chemical analysis of the brains of kif3b mutant mice and human schizophrenia patients revealed damage to CRMP2, a protein used for the assembly of actin. 

As such, the researchers proposed that betaine may help patients with schizophrenia by preventing a kind of chemical damage, known as carbonyl stress, that leads to CRMP2 dysfunction. This comes especially as postmortem brain scans have found that CRMP2 is the protein that undergoes the most carbonyl stress in the brain. 

By protecting CRMP2 from damage, the researchers propose that betaine may allow kif3b mutant neurons to build proper cell structures. With these structures built, the remaining functional KIF3B proteins can then transport cargo around the cells, something that, once extrapolated, may reduce some symptoms of schizophrenia. 

While the researchers don’t encourage people to take betaine supplements without a doctor’s recommendation, they say that one day, after further tests and trials, they may be able to be repurposed to treat schizophrenia. This comes especially as the supplement is already known to be safe from pre-existing clinical use. 

 

Sources: Neuroscience NewsCell

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
MAR 12, 2022
Cannabis Sciences
The Role of Cannabinoid Receptors
MAR 12, 2022
The Role of Cannabinoid Receptors
A recent review of research on cannabinoid receptors and their influence on signaling pathways provides insights into ho ...
MAR 29, 2022
Drug Discovery & Development
Nasal Spray Shows Promise Against All Variants of SARS-CoV-2
MAR 29, 2022
Nasal Spray Shows Promise Against All Variants of SARS-CoV-2
A compound delivered via a nasal spray can prevent and treat various COVID-19 variants in mice. The corresponding study ...
APR 28, 2022
Drug Discovery & Development
Keto Molecule Shows Promise for Treating Colorectal Cancer
APR 28, 2022
Keto Molecule Shows Promise for Treating Colorectal Cancer
A molecule produced when on low-carbohydrate ketogenic diets suppresses the growth of colorectal tumors in the lab. The ...
MAY 09, 2022
Cancer
A Gel Implant Protects from Cancer Recurrence
MAY 09, 2022
A Gel Implant Protects from Cancer Recurrence
Following a successful course of cancer treatment, a patient may enter remission. Remission, classified as either partia ...
MAY 25, 2022
Neuroscience
Exploring Drug Targets in Neurodegenerative Diseases
MAY 25, 2022
Exploring Drug Targets in Neurodegenerative Diseases
Introduction Life expectancy has increased globally over the last several decades. However, longer life expectancy comes ...
MAY 23, 2022
Drug Discovery & Development
A Possible Therapy for Infantile Spasms
MAY 23, 2022
A Possible Therapy for Infantile Spasms
Researchers at Texas Children’s Hospital have identified a possible cause of infantile spasms (IS) as well as a po ...
Loading Comments...